The Journal of the American Medical Association (JAMA) has published key data on cytisinicline, from US specialty pharma Achieve Life Sciences (Nasdaq: ACHV).
These results are from the Phase III ORCA-2 randomized placebo-controlled trial of cytisinicline as a treatment for smoking cessation, the first large trial of this medication conducted in the USA.
The study authors concluded that cytisinicline demonstrated “smoking cessation efficacy and excellent tolerability” in adult smokers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze